This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Study Finds Corus CAD To Be More Accurate In Excluding The Diagnosis Of Obstructive Coronary Artery Disease In Women Than Standard Diagnostic Methods

PALO ALTO, Calif., March 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced data demonstrating that Corus® CAD, the only clinically validated gene expression test for the assessment of obstructive coronary artery disease (CAD), has higher diagnostic accuracy than commonly used risk assessment modalities including symptom evaluation and myocardial perfusion imaging (MPI) in women. The sex-specific analysis of the PREDICT ( Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Trial was presented during a poster session at the Women's Health 2013: 21 st Annual Congress, which took place in Washington D.C. from March 22 nd - 24 th.

(Logo:  http://photos.prnewswire.com/prnh/20130219/MM60898 )

There is a growing body of clinical evidence confirming that standard diagnostic approaches used to evaluate patients for obstructive CAD lead to many unnecessary noninvasive and invasive procedures such as MPI, stress echocardiogram, computed tomography angiography and coronary angiography, especially in women [1]. According to the results of the PREDICT Trial, MPI was not a significant predictor of obstructive CAD in women. This may be due to the presence of breast and fatty tissue in women, which leads to a higher rate of false-positive diagnoses [2] and, consequently, a higher rate of unnecessary referrals for additional invasive testing. The study also found that chest pain and other clinical factors are not reliable predictors of obstructive CAD in women. The traditional chest pain symptom classification as defined by Diamond and Forrester is helpful in diagnosing men, but does not correspond to presence of obstructive CAD in women. Furthermore, women with obstructive CAD tend to present with atypical, nonspecific symptoms such as shortness of breath, fatigue, and abdominal pain. Only the Corus CAD score and dyslipidemia were associated with the findings of obstructive CAD in women.

"Since the symptoms of coronary disease in women are not as well defined as in men, clinicians cannot use the same assessment criteria in women as they do in men," said Alexandra Lansky, MD, Associate Professor of Medicine and Director of the Cardiovascular Research Center, Yale University School of Medicine, the senior author of the study and one of the PREDICT co-investigators. "Women have more angina and less obstructive coronary artery disease compared to age-matched men and are significantly over-referred to invasive coronary angiography, as current noninvasive diagnostic approaches have limitations in women. Women need tests that are both specific to their biology and can reliably assess the origin of their symptoms. Corus CAD is the only sex-specific test for evaluating obstructive CAD and represents a paradigm shift in how clinicians may diagnose heart disease in women, who account for half of the U.S. population."  

The PREDICT cohorts analyzed included 1,160 stable non-diabetic men and women referred for cardiac catheterization with typical and atypical symptoms suggestive of obstructive CAD or who were asymptomatic with a high risk of CAD: a substudy of 492 women was included in this sex-specific analysis. Of the women referred to invasive coronary angiography with abnormal MPI results (N=295), only 22 percent had obstructive CAD upon invasive coronary angiography. The study showed that Corus CAD results were more accurate than MPI and were significantly associated with the extent and severity of obstructive CAD.  Corus CAD was a significant classifier of obstructive CAD in the overall population (p<0.001) and in the male (p=0.001) and female (p<0.001) subgroups separately, whereas MPI was not found to be an independent indicator of obstructive CAD. Each 10-point increase in the Corus CAD score was associated with a twofold increase in the likelihood of obstructive CAD in men, and a 3.4-fold increase in the likelihood of obstructive CAD in women. The results demonstrate the improved ability of Corus CAD to safely exclude obstructive CAD as a diagnosis, particularly in women.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs